Chitosan-graft-(PEI-β-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery

Yuan, Ping; Liu, Chengde; Zhang, Zhongxing; Liu, Kerh Li; Chen, Jianhai; Li, Jun

doi:10.1016/j.biomaterials.2011.07.038

Cited by 172 publications

(117 citation statements)

References 58 publications

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…[1][2][3] In the past decade, developing the therapeutic plasmid DNA ( pDNA) and RNA interference (RNAi) technology has attracted much attention as a promising strategy for therapeutic intervention of various human diseases. [4,5] Despite high promise, safe and efficient delivery of nucleic acids into cells is still a bottleneck for the successful gene therapy or gene knockdown. [6,7] Thus, there is an unmet need to develop carriers, which can protect the therapeutic genes and transport them into targeted sites where they can exert their functions while retaining their transfection efficiency.…”

Section: Introductionmentioning

confidence: 99%

A Serum‐Tolerant Hydroxyl‐Modified Polyethylenimine as Versatile Carriers of pDNA/siRNA

Dong

Lin

Chen

et al. 2013

Macromolecular Bioscience

View full text Add to dashboard Cite

The polyethylenimine (PEI) derivatives (PTn) are prepared by treating PEI25k with Tris(hydroxymethyl) acrylamidomethane via the Michael addition. These PTns can effectively condense nucleic acids into nanosized particles with positive surface charges. The PTns show lower cytotoxicity and better serum-resistant capacity than PEI25k. Specially, the transfection efficiency of PT26/DNA is 29-fold higher than that of PEI25k in HeLa cells in serum-containing medium. The PTn/siRNA complexes show superior knockdown effect in CT26 cells in serum-containing medium. In addition, flow cytometry analysis shows that the PTns can efficiently mediate the entry of nucleic acids into the cell. Thus, PTns are potentially applicable as non-viral carriers of nucleic acids and warrant further development for use in gene therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

A Serum‐Tolerant Hydroxyl‐Modified Polyethylenimine as Versatile Carriers of pDNA/siRNA

Dong

Lin

Chen

et al. 2013

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…However, green fl uorescence, as a result of HCP-mediated pEGFP gene expression, was observed to distribute evenly inside the cells, which is similar to typical green fl uorescence protein expression after carrier-mediated gene transfection. [ 33 ] These experiments strongly indicate that the expressed TSA protein possesses a high affi nity towards the LLC cell membrane and is able to fi rmly anchor into the LLC cell membrane.…”

Section: In Vivo T Cell Immunity and Cytokine Productionmentioning

confidence: 95%

Synergistic Enhancement of Lung Cancer Therapy Through Nanocarrier‐Mediated Sequential Delivery of Superantigen and Tyrosin Kinase Inhibitor

Xing

et al. 2014

Adv Funct Materials

Self Cite

View full text Add to dashboard Cite

Gefitinib (GFT) and other tyrosine kinase inhibitors (TKIs) have been widely used for the treatment of advanced or metastatic lung cancer due to their reduced side effects when compared to classic cytotoxic chemotherapeutic agents. However, both intrinsic and acquired resistance often hinders the effectiveness of TKIs. Based on recent findings that the outcome of chemotherapy can be influenced by the host immune system at multiple levels, an exploration of whether activating antitumor immunity improves the efficacy of the targeted cancer therapy of TKIs is undertaken. To this end, a cationic carrier is used to deliver superantigen and GFT in a simultaneous or sequential manner. The sequential delivery of superantigen and GFT can significantly enhance T cell immunity, promote cytokine production, inhibit tumor growth, and prolong survival time in tumor models with lung carcinoma xenografts. Most importantly, dual sequential treatment reveals a synergistic effect on tumor inhibition, which is much more effective than the monotherapy of either GFT or pTSA, as well as the combined treatment through simultaneous codelivery of pTSA and GFT together. This study demonstrates the important contribution of immunotherapy to targeted molecular therapy and opens up new possibilities for treating a wide spectrum of cancers.

show abstract

“…PEG-SS-PLL/siVEGF, PEG-PLL/siVEGF, polyethylenimine (PEI)/siVEGF, and Lipofectamine/siVEGF complexes were mixed at different ratios of vector to siVEGF (0, 0.1, 0.2, 0.4, 0.6, 0.8, 1, and 1.2). The HepG2 cells were transfected with PEG-SS-PLL/siVEGF, PEG-PLL/siVEGF, PEI/siVEGF, or Lipofectamine/siVEGF at different concentrations (50, 100, 150, or 200 nM) or PBS for 48 hours, followed by a typical siRNA-transfection experiment, 30 and cell viability was evaluated by MTT assay. In brief, 20 μL of MTT solution at 5 mg/mL (Thermo Fisher Scientific) was added to each well and incubated with the cells for 4 hours, then, the medium was removed and 150 μL of dimethyl sulfoxide added to each well.…”

Section: Mtt Assay For Cell Viabilitymentioning

confidence: 99%

Polyethylene glycol–poly(ε-benzyloxycarbonyl-L-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma

Wang¹,

Gao²,

Gu³

et al. 2017

IJN

View full text Add to dashboard Cite

A polyethylene glycol–poly(ε-benzyloxycarbonyl- l -lysine) (PEG-SS-PLL) block copolymer based on a disulfide-linked, novel biodegradable catiomer bearing a PEG-sheddable shell was developed to avoid “PEG dilemma” in nanoparticle intracellular tracking of PEG-PLL where PEG was nondegradable. However, PEG-SS-PLL catiomers have not been used to deliver small interfering VEGF RNA (siVEGF) in antiangiogenesis gene therapy. In this study, we aimed to investigate whether this novel biodegradable catiomer can deliver siVEGF into cancer cells and at the same time have an antitumor effect in a xenograft mouse model. It was found that PEG-SS-PLL efficiently delivered siVEGF with negligible cytotoxicity, and significantly decreased the expression of VEGF at both the messenger-RNA and protein levels both in vitro and in vivo, and thus tumor growth was inhibited. Our findings demonstrated that PEG-SS-PLL/siVEGF could potentially be applied to antiangiogenesis gene therapy for hepatocellular carcinoma.

show abstract

Chitosan-graft-(PEI-β-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery

Cited by 172 publications

References 58 publications

A Serum‐Tolerant Hydroxyl‐Modified Polyethylenimine as Versatile Carriers of pDNA/siRNA

A Serum‐Tolerant Hydroxyl‐Modified Polyethylenimine as Versatile Carriers of pDNA/siRNA

Synergistic Enhancement of Lung Cancer Therapy Through Nanocarrier‐Mediated Sequential Delivery of Superantigen and Tyrosin Kinase Inhibitor

Polyethylene glycol–poly(ε-benzyloxycarbonyl-L-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma

Contact Info

Product

Resources

About

Chitosan-graft-(PEI-β-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery

Cited by 172 publications

References 58 publications

A Serum‐Tolerant Hydroxyl‐Modified Polyethylenimine as Versatile Carriers of pDNA/siRNA

A Serum‐Tolerant Hydroxyl‐Modified Polyethylenimine as Versatile Carriers of pDNA/siRNA

Synergistic Enhancement of Lung Cancer Therapy Through Nanocarrier‐Mediated Sequential Delivery of Superantigen and Tyrosin Kinase Inhibitor

Polyethylene glycol&ndash;poly(&epsilon;-benzyloxycarbonyl-L-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma

Contact Info

Product

Resources

About

Polyethylene glycol–poly(ε-benzyloxycarbonyl-L-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma